|
|
|
|
|
|
By Vadim Klyushnichenko, Outsourced Pharma Advisory Board Member | In biologics and cell and gene therapy (CGT), selecting and managing a CDMO has become a strategic imperative. Unfortunately, traditional approaches to external partners can fall short. But now AI is reshaping this landscape. Analysis from an Outsourced Pharma Board member. | |
|
|
|
| Setting The Standard For Plasmid DNA Production | White Paper | Boehringer Ingelheim Biopharmaceuticals GmbH | Discover how Boehringer Ingelheim’s expertise in plasmid DNA manufacturing can propel your innovative therapies forward and transform patient care. |
|
|
|
|
| Soluble Versus Insoluble Expression In Microbial Fermentation | Article | By Nikolay Krumov and Jonas Mueller, Lonza | Expression of inclusion bodies has historically suffered a bad reputation in the industry. So, how do these two routes, soluble and insoluble, compare in terms of their advantages and challenges? |
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
